Overview

This trial is active, not recruiting.

Condition chronic kidney disease
Sponsor Ankara Education and Research Hospital
Start date March 2008
End date May 2011
Trial size 90 participants
Trial identifier NCT01317173, NEPH001

Summary

Chronic kidney disease is a progressive disorder that has been influenced with many factors. Most of the patients has altered Ca P metabolism and these dis orders are the contributing factors of the disease progression. It has been recently documented that FGF23 and Klotho are the key factors of PTH secretion Ca-P metabolism. This study aimed to evaluate the impact of Klotho and FGF23 on the progression of stage 3-4 chronic kidney disease.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Arm
Serum creatinin level rise more than 2 times
Serum creatinin level rise less than 2 times

Primary Outcomes

Measure
Progression of kidney disease
time frame: continuous measurement of kidney functions 3 monthly for two years or until the outcome reached

Secondary Outcomes

Measure
Evaluation of Ca P metabolism
time frame: 3 monthly for two years or until the outcome reached

Eligibility Criteria

Male or female participants from 18 years up to 65 years old.

Inclusion Criteria: - Non-diabetic chronic kidney disease Exclusion Criteria: - Presence of DM - Actively using calcium based phosphorus binder of vitamin D

Additional Information

Official title The Impact of FGF23 and Klotho on Progression of Chronic Kidney Disease
Trial information was received from ClinicalTrials.gov and was last updated in March 2011.
Information provided to ClinicalTrials.gov by Ankara Education and Research Hospital.